ASCLF Stock - Ascletis Pharma Inc.
Unlock GoAI Insights for ASCLF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.28M | $56.60M | $54.09M | $76.88M | $35.00M |
| Gross Profit | $735,000 | $25.99M | $-24,692,000 | $39.17M | $-23,497,000 |
| Gross Margin | 57.3% | 45.9% | -45.6% | 51.0% | -67.1% |
| Operating Income | $-295,419,000 | $-300,208,000 | $-343,977,999 | $-224,966,000 | $-217,112,000 |
| Net Income | $-300,936,000 | $-144,715,000 | $-314,843,000 | $-199,017,000 | $-209,241,000 |
| Net Margin | -23455.7% | -255.7% | -582.1% | -258.9% | -597.8% |
| EPS | $-0.30 | $-0.13 | $-0.29 | $-0.18 | $-0.20 |
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB) and human immunodeficiency virus functional cure; ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.
Visit WebsiteEarnings History & Surprises
ASCLFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 15, 2025 | $-0.02 | $-0.01 | +31.0% | ✓ BEAT |
Q1 2025 | Mar 26, 2025 | $-0.02 | $-0.02 | -13.3% | ✗ MISS |
Q4 2024 | Dec 31, 2024 | — | $-0.02 | — | — |
Q3 2024 | Aug 30, 2024 | $-0.02 | $-0.02 | -6.8% | ✗ MISS |
Q2 2024 | May 23, 2024 | $-0.01 | $-0.02 | -71.4% | ✗ MISS |
Q4 2023 | Dec 31, 2023 | — | $-0.02 | — | — |
Q2 2023 | Jun 30, 2023 | $-0.00 | $-0.00 | +23.9% | ✓ BEAT |
Q1 2023 | Mar 19, 2023 | $-0.02 | $-0.07 | -206.6% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | — | $-0.03 | — | — |
Q3 2022 | Aug 22, 2022 | $-0.01 | $-0.01 | -15.6% | ✗ MISS |
Q1 2022 | Mar 21, 2022 | $-0.01 | $-0.01 | +11.1% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | — | $-0.01 | — | — |
Q3 2021 | Aug 26, 2021 | $-0.01 | $-0.02 | -44.0% | ✗ MISS |
Q1 2021 | Mar 29, 2021 | $-0.00 | — | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.02 | — | — |
Q3 2020 | Aug 28, 2020 | $-0.00 | $-0.01 | -393.0% | ✗ MISS |
Q1 2020 | Mar 24, 2020 | $-0.01 | $-0.01 | +0.6% | ✓ BEAT |
Q4 2019 | Dec 31, 2019 | — | $-0.01 | — | — |
Q3 2019 | Aug 29, 2019 | — | $-0.01 | — | — |
Q1 2019 | Mar 24, 2019 | — | — | — | — |
Latest News
Sagimet's License Partner Ascletis Pharma Issues Statement That China's National Medical Products Administration Accepts NDA For Denifanstat For Acne Treatment
📈 PositiveSagimet Biosciences Says Ascletis Gets China NMPA NDA Acceptance For Denifanstat ASC40, First-In-Class Oral FASN Inhibitor For Moderate-To-Severe Acne After Phase III Trial Meets All Primary And Key Secondary Endpoints
📈 PositiveFrequently Asked Questions about ASCLF
What is ASCLF's current stock price?
What is the analyst price target for ASCLF?
What sector is Ascletis Pharma Inc. in?
What is ASCLF's market cap?
Does ASCLF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ASCLF for comparison